Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, announced it will host a live webinar on September 23 at 12:30 p.m. Eastern to present the business model, development roadmap, and value proposition of Open-Medicine AI (OMAI), its wholly owned subsidiary developing a multi-agentic AI platform for end-to-end therapeutic development. The session, led by Panna Sharma, founder and CEO of Open-Medicine AI, will cover OMAI platform architecture, expansion beyond rare cancers into additional disease categories and therapeutic modalities, and its planned subscription and enterprise licensing business model.
The webinar comes as AI-driven drug discovery gains traction, potentially reducing the time and cost of bringing new therapies to market. Lantern Pharma’s RADR platform integrates large-scale genomic and biological data with machine learning to identify patients most likely to benefit from its therapies, guiding biomarker-driven clinical development. The company’s pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. For investors, the webinar offers insight into how Lantern plans to monetize its AI capabilities beyond internal drug development, potentially opening new revenue streams through licensing.
The move to expand OMAI beyond rare cancers into broader disease categories and therapeutic modalities signals a strategic shift that could position Lantern as a key player in the AI-powered drug development space. As the pharmaceutical industry increasingly adopts AI to streamline R&D, Lantern’s multi-agentic platform could appeal to partners seeking to accelerate their own pipelines. The planned subscription and enterprise licensing model suggests a scalable business approach that may attract both small biotechs and large pharmaceutical companies.
For the broader biotech sector, Lantern’s progress with OMAI underscores the growing convergence of AI and genomics in precision medicine. If successful, the platform could set a precedent for how AI tools are commercialized, potentially lowering barriers for smaller companies to leverage advanced computational approaches. This could lead to more efficient drug development and, ultimately, faster access to new treatments for patients.
Investors and industry watchers can view the full press release at https://ibn.fm/U9lmN. The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN. BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, is one of 75+ brands within the Dynamic Brand Portfolio at IBN. The platform delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and enhanced press release enhancement to ensure maximum impact. Additionally, social media distribution via IBN reaches millions of followers, and a full array of tailored corporate communications solutions is available. For more information, visit BioMedWire.
